Development of a Bayesian belief network model for personalized prognostic risk assessment in colon carcinomatosis

American Surgeon

Volumn 77, Issue 2, 2011, Pages 221-230

  Stojadinovic, Alexander ^a,b   Nissan, Aviram ^b,c   Eberhardt, John ^d   Chua, Terence C ^e   Pelz, Joerg O W ^f   Esquivel, Jesus ^b,g  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b United States Military Cancer Institute   (United States)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d DecisionQ Corporation   (United States)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f UNIVERSITY OF WÜRZBURG   (Germany)

^g ST AGNES HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; MITOMYCIN C;

ADOLESCENT; ADULT; AGED; ARTICLE; BAYESIAN LEARNING; CANCER CHEMOTHERAPY; CANCER STAGING; CARCINOMATOSIS; CLASSIFIER; CLINICAL DECISION MAKING; CLINICAL FEATURE; COLON TUMOR; CYTOREDUCTIVE SURGERY; DECISION SUPPORT SYSTEM; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; HYPERTHERMIC THERAPY; KARNOFSKY PERFORMANCE STATUS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PATIENT CARE; PATIENT SELECTION; PERITONEUM CANCER; PREDICTION; PREOPERATIVE EVALUATION; PROBABILITY; PROGNOSIS; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT;

ADOLESCENT; ADULT; AGED; ALGORITHMS; BAYES THEOREM; COLONIC NEOPLASMS; DECISION SUPPORT TECHNIQUES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; INFUSIONS, PARENTERAL; MALE; MIDDLE AGED; PERITONEAL NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; ROC CURVE; YOUNG ADULT;

EID: 79952407655     PISSN: 00031348     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Chu DZ, Lang NP, Thompson C, et al. Peritoneal carcinomatosis in non-gynecologic malignancy: A prospective study of prognostic factors. Cancer 1989;63:364-7. (Pubitemid 19035034)
2. Jayne DG, Fook S, Loi C, et al. Peritoneal carcinomatosis from colorectal cancer. Br J Surg 2002;89:1545-50. (Pubitemid 35404323)
3. Jacquet P, Vidal-Jove J, Zhu B, Sugarbaker P. Peritoneal carcinomatosis from gastrointestinal malignancy: natural history and new prospects for management. Acta Chir Belg 1994;94:191-7.
4. Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: Results of the EVOCAPE 1 multi-centric prospective study. Cancer 2000;88:58-63.
5. Jayne DG, Fook S, Loi C, et al. Peritoneal carcinomatosis from colorectal cancer. Br J Surg 2002;89:1545-50. (Pubitemid 35404323)
6. Esquivel J, Elias D, Baratti D, et al. Consensus statement on the locoregional treatment of colorectal cancer with peritoneal dissemination. J Surg Oncol 2008;98:263-7.
7. Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: A multi-institutional study. J Clin Oncol 2004;22:3284-92. (Pubitemid 41103684)
8. Shen P, Thai K, Stewart JH, et al. Peritoneal surface disease from colorectal cancer; Comparison to the hepatic metastases surgical paradigm in optimally resected patients. Ann Surg Oncol 2008;15:3422-32. Epub 2008 Sep 11.
9. Verwaal V, Ruth S, Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003;21:3737-43. (Pubitemid 46606227)
10. Okamoto T, Yamazaki K, Kanbe M, et al. Probability of axillary lymph node metastasis when sentinel lymph node biopsy is negative in women with clinically node negative breast cancer: a Bayesian approach. Breast Cancer 2005;12:203-10.
11. Berchuck A, Iversen ES, Lancaster JM, et al. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res 2005;11:3686-96. (Pubitemid 40685585)
12. Berry DA, Inoue L, Shen Y, et al. Modeling the impact of treatment and screening on U.S. breast cancer mortality: a Bayesian approach. J Natl Cancer Inst Monogr 2006;36:30-6.
13. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26. (Pubitemid 40051905)
14. Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al. DD3: A new prostate-specific gene, highly over expressed in prostate cancer. Cancer Res 1999;59:5975-9. (Pubitemid 30004960)
15. de Kok JB, Verhaegh GW, Roelofs RW, et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 2002;62:2695-8. (Pubitemid 34462754)
16. Hessels D, Klein Gunnewiek JM, van Oort I, et al. DD3 (PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003;44:8-15.
17. Weiser MR, Landmann RG, Kattan MW, et al. Individualized prediction of colon cancer recurrence using a nomogram. J Clin Oncol 2008;26:380-5. (Pubitemid 351171688)
18. Massacesi C, Norman A, Price T, et al. A clinical nomogram for predicting long-term survival in advanced colorectal cancer. Eur J Cancer 2000;36:2044-52.
19. Kattan MW, Gonen M, Jarnagin WR, et al. A nomogram for predicting disease-specific survival after hepatic resection for metastatic colorectal cancer. Ann Surg 2008;247:282-7. (Pubitemid 351156771)
20. Kanemitsu Y, Kato T, Hirai T, Yasui K. Preoperative probability model for predicting overall survival after resection of pulmonary metastases from colorectal cancer. Br J Surg 2004;91:112-20. (Pubitemid 38122060)
21. Ramesh AN, Kambhampati C, Monson JR, et al. Artificial intelligence in medicine. Ann R Coll Surg Engl 2004;86:334-8. (Pubitemid 39232546)